ARQT · Arcutis Biotherapeutics, Inc. — research history

Score of 17 reflects absent insider conviction, high short interest (13.8%), and elevated RSI (72) into earnings. The active anti-signals (insider selling cluster, dilution, concentration) are valid and actionable; combined with Scout's range-bound verdict and lack of a clear income or directional edge, this dossier fails to clear the publication bar.

Score of 17 reflects absent insider conviction, high short interest (13.8%), and elevated RSI (72) into earnings. The active anti-signals (insider selling cluster, dilution, concentration) are valid and actionable; combined with Scout's range-bound verdict and lack of a clear income or directional edge, this dossier fails to clear the publication bar.

Arcutis is a commercial-stage dermatology biotech with its lead product ZORYVE (topical roflumilast) posting 65% YoY revenue growth to $105M in Q1 FY26. The Form 4 cluster trigger was misleading — the 10 filings over 14 days were predominantly pre-scheduled 10b5-1 sales and RSU vesting transactions, not genuine insider conviction purchases. Patrick Heron's sole 'acquisition' was an RSU grant at $0 exercise price (not a cash purchase), while three directors collectively sold ~$240K under scheduled plans in May-June — all BELOW current prices ($22.99-$24.62 vs $26.21 spot). No open-market CEO/CFO/Director purchases of any material size were found. The bull case rests on strong ZORYVE growth, an analyst consensus target of $35 (+33% upside), FCF-positive status, and a pediatric label expansion catalyst via sNDA filing (PDUFA expected within 6-9 months). The bearish counter is that the Form 4 cluster was almost entirely scheduled selling (anti-signal per methodology), RSI is elevated at ~72 entering earnings (August 5), short interest is high at 13.8% of float, and the stock is already near its 52-week high with limited near-term re-rating catalysts beyond routine commercial execution.

Score falls well below the 45-point threshold due to zero smart-money or mispricing signals, lack of sustained bullish options flow, and unproven catalyst timing. The dossier explicitly flags a range-bound setup with revenue concentration and historical dilution risks, making it unsuitable for publication or paper-tracking at this time.

Arcutis is a commercial-stage dermatology biotech that has crossed into cash-flow positivity while posting 60%+ revenue growth on its ZORYVE (topical roflumilast) franchise. An sNDA for pediatric AD expansion (infants down to 3 months) was submitted in April 2026 and awaits FDA action — a material label expansion catalyst with only one competing non-steroidal option. All June 9 Form 4s were director RSU grants at $0 cost basis, not open-market purchases; no insider buying signal is present. Options flow shows a heavily bearish put/call ratio (4.17) on moderate volume, consistent with protective hedging by existing holders rather than new directional bets. The stock trades at ~21x forward P/E against 60%+ revenue growth — reasonable but not cheap — with analyst consensus near $35 vs current $24.38, implying the market has not fully priced in the pediatric label expansion upside or continued ZORYVE trajectory.

Arcutis is a commercial-stage dermatology biotech with ZORYVE franchise revenue growing 65% YoY ($105M Q1 2026) and approaching FCF breakeven. Multiple pediatric label expansions are pending (PDUFA June 29 for plaque psoriasis age 2-5, sNDA submitted April 2026 for atopic dermatitis down to 3 months). However, all recent insider transactions over the past 90 days are SELLs — exclusively tax-withholding and scheduled 10b5-1 sales on RSU vesting by CFO, CLO, CMO, and a board director. No open-market purchase (P-code) activity exists. The stock trades ~31% below its 52-week high of $31.77, below both the 50DMA ($22.51) and 200DMA ($23.66), suggesting technical deterioration from November's peak. While analyst consensus targets ~$35 (strong buy, 8 analysts), the absence of any insider buying conviction combined with a stock that is near fair value rather than dramatically mispriced makes this a hold-not-chase situation at current levels.

Critically low score due to zero insider buying, broken technicals, and absence of a near-term catalyst beyond August earnings. While elevated IV supports an income structure, the dossier flags concentration and dilution risks that outweigh the setup, and the lack of a directional edge makes publishing unjustified.

Arcutis is a commercial-stage dermatology company whose lead product ZORYVE (topical roflumilast) delivered 65% YoY revenue growth in Q1 2026 ($105.4M). The pipeline trigger was a Form 4 cluster — however, every single filing examined from the May 2026 window represents routine tax-withholding sells via pre-set 10b5-1 plans by the CEO (3,172 shares), CLO (8,256 shares), CFO (1,341 shares), CMO (684 shares), and a director (7,144 shares). Zero open-market purchases. The stock collapsed ~34% from its November 2025 high ($31.20) to $20.86 following Q1 earnings that beat top-line but showed a large EPS miss driven by R&D investment. Analysts cluster at $34–36 targets — meaningful upside vs current price, but the near-term setup lacks urgency: stock below both 50- and 200-DMA, no insider buying signal, next catalyst is August earnings. IV runs 67–68% ATM, creating a viable covered-call / strangle income structure on rallies.

Dossier flags material anti-signals (single-product revenue concentration and dilution overhang) and lacks the quantitative catalysts, smart-money cluster, or technical momentum required to clear the scoring threshold; the elevated IV does not compensate for the asymmetric risk profile of a commercial-stage biotech with a binary FDA event and no structural earnings tailwind.

Arcutis reported strong Q1 2026 net product revenue of $105.4M (+65% YoY) and turned cash-flow positive for the first time in company history ($2.2M operating CF). However, shares dropped ~11% post-earnings on a guidance-related selloff that appears overdone relative to confirmed fundamentals. Seven Form 4 filings in 14 days cluster around May 4 and May 11, with multiple insiders buying open-market at $21-$22 — precisely near the bottom of this drawdown from the 52-week high of $31.77. A pending FDA sNDA for ZORYVE cream expansion to infants as young as 3 months (submitted April 27) represents a named catalyst that could re-rate the stock, and several Wall Street analysts are clustering around $34-35 targets. The stock is below both its 50DMA and 200DMA with RSI in neutral territory (~41), consistent with accumulation rather than distribution.